Aurinia Pharmaceuticals Reports Second Quarter and Six Months 2023 Financial and Operational ResultsBusiness Wire • 08/03/23
Aurinia Pharmaceuticals to Release Second Quarter Financial and Operational Results on August 3, 2023Business Wire • 07/20/23
Long Term Phase 3 Data Published in Arthritis & Rheumatology Shows LUPKYNIS® (voclosporin) Preserved Kidney Function Up to Three Years in Lupus Nephritis Patients with No New or Unexpected Adverse EventsBusiness Wire • 07/19/23
MKT Capital Pleased with Aurinia's Commencement of a Strategic Review ProcessBusiness Wire • 07/06/23
Aurinia Surges As It Explores 'Strategic Alternatives,' Including A Potential BuyoutInvestors Business Daily • 06/30/23
Aurinia Pharmaceuticals Share Surge Shows Investor Support for Board Reboot, Strategic Review24/7 Wall Street • 06/30/23
Aurinia Board of Directors Announces Exploration of Strategic Alternatives to Maximize Shareholder ValueBusiness Wire • 06/29/23
Aurinia Showcases Three Oral Presentations for LUPKYNIS® (voclosporin) at 2023 European Renal Association Annual Meeting in Milan, ItalyBusiness Wire • 06/20/23
LUPKYNIS® (voclosporin) Achieved Significantly Higher Renal Response in Lupus Nephritis Patients with High Proteinuria Compared to Patients Treated with MMF and Low Dose Steroids AloneBusiness Wire • 06/01/23
MKT Capital Calls on Aurinia's Board of Directors to Respect the Message Sent by Shareholders at 2023 Annual MeetingBusiness Wire • 06/01/23
Aurinia Files Form S-8 to Register Shares Underlying Previously Disclosed Inducement Awards for Newly Hired EmployeesBusiness Wire • 05/26/23
MKT Capital Thanks Fellow Shareholders for Their Strong Support at Aurinia's 2023 Annual MeetingBusiness Wire • 05/17/23
Here's Why Aurinia Pharmaceuticals (AUPH) is a Great Momentum Stock to BuyZacks Investment Research • 05/11/23
MKT Capital Comments on Aurinia's Largest Shareholder's Plans to WITHHOLD Support for the Majority of the Board at the 2023 Annual MeetingBusiness Wire • 05/11/23
Aurinia Pharmaceuticals Announces Kidney Biopsies Sub-study Data from the LUPKYNIS® (voclosporin) AURORA 2 Clinical Trial Presented at Congress of Clinical Rheumatology East ConferenceBusiness Wire • 05/09/23
MKT Capital Issues Statement Regarding Aurinia's Disappointing First Quarter 2023 Financial ResultsBusiness Wire • 05/05/23
Aurinia Pharmaceuticals Reports First Quarter 2023 Financial and Operational ResultsBusiness Wire • 05/04/23
ISS Recommends Aurinia Shareholders Vote Against the Company's Named Executive Officers' CompensationBusiness Wire • 05/03/23